PUBLICATIONS FROM THE FINNISH CANCER REGISTRY 1953-2016 by L. Määttänen 08.02.2016
2015 2014 2013 2012 and earlier
Kilpeläinen, T.P., Tammela, T.L.J., Malila, N., Hakama, M., Santti, H., Määttänen, L., Stenman, U.-H., Kujala, P. and Auvinen, A.: The Finnish prostate cancer screening trial: analyses on the screening failures. Int. J. Cancer 2015; 136: 2437-2443.
Pashayan, N., Pharoah, P.D.P., Schleutker, J., Talala, K., Tammela, T.L.J., Määttänen, L., Harrington, P., Tyrer, J., Eeles, R., Duffy, S.W. and Auvinen, A.: Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. Br. J. Cancer 2015; 1-8/doi: 10.1038/bjc.2015.289.
Pashayan, N., Pharoah, P.D.P., Schleutker, J., Talala, K., Tammela, T.L.J., Määttänen, L., Harrington, P., Tyrer, J., Eeles, R., Duffy, S.W. and Auvinen, A.: Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. Br. J. Cancer 2015; 113: 1086-1093.
Saarimäki, L., Tammela, T.L., Määttänen, L., Taari, K., Kujala, P.M., Raitanen, J. and Auvinen, A.: Family history in the Finnish Prostate Cancer Screening Trial. Int. J. Cancer 2015; 136: 2172-2177.
Booth, N., Rissanen, P., Tammela, T.L.J., Määttänen, L., Taari, K. and Auvinen, A.: Health-related quality of life in the Finnish trial of screening for prostate cancer. Eur. Urol. 2014; 65: 39-47.
Schröder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., Määttänen, L., Lilja, H., Denis, L., Recker, F., Paez, A., Bangma, C.H., Carlsson, S., Puliti, D., Villers, A., Rebillard, X., Hakama, M., Stenman, U.-H., Kujala, P., Taari, K., Aus, G., Huber, A., van der Kwast, T.H., van Schaik, R.H.N., de Koning, H.J., Moss, S.M. and Auvinen, A. for the ERSPC Investigators:
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; 384: 2027-2035.
Veitonmäki, T., Murtola, T.J., Määttänen, L., Taari, K., Stenman, U.-H., Tammela, T.L.J. and Auvinen, A.: Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. Br. J. Cancer 2014; 111: 1421-1431.
Kilpeläinen, T.P., Tammela, T.L., Malila, N., Hakama, M., Santti, H., Määttänen, L., Stenman, U.-H., Kujala, P. and Auvinen, A.: Prostate cancer mortality in the Finnish randomized screening trial. J. Natl. Cancer Inst. 2013; 105: 719-725.
Vasarainen, H., Malmi, H., Määttänen, L., Ruutu, M., Tammela, T., Taari, K., Rannikko, A. and Auvinen, A.: Effects of prostate cancer screening on health-related quality of life: results of the Finnish arm of the European randomized screening trial (ERSPC). Acta Oncol. 2013; 52: 1615-1621.
Yli-Hemminki, T.H., Laurila, M., Auvinen, A., Määttänen, L., Huhtala, H., Tammela, T.L.J. and Kujala, P.M.: Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. BJU Int. 2013; 112: 735-741.
Schröder, F.H., Hugosson, J., Carlsson, S., Tammela, T., Määttänen, L., Auvinen, A., Kwiatkowski, M., Recker, F. and Roobol, M.J.: Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur. Urol. 2012; 62: 745-752.
Schröder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L.J., Recker, F., Paez, A., Määttänen, L., Bangma, C.H., Aus, G., Carlsson, S., Villers, A., Rebillard, X., van der Kwast, T., Kujala, P.M., Blijenberg, B.G., Stenman, U.-H., Huber, A., Taari, K., Hakama, M., Moss, S.M., de Koning, H.J. and Auvinen, A. for the ERSPC Investigators:
Prostate cancer mortality at 11 years of follow-up. N. Engl. J. Med. 2012; 366: 981-990.
Wu, G.H.-M., Auvinen, A., Määttänen, L., Tammela, T.L.J., Stenman, U.-H., Hakama, M., Yen, A.M.-F. and Chen, H.-H.: Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. Int. J. Cancer 2012; 131: 1367-1375.
Kilpeläinen, T.P., Tammela, T.L.J., Roobol, M., Hugosson, J., Ciatto, S., Nelen, V., Moss, S., Määttänen, L. and Auvinen, A.: False-positive screening results in the European randomized study of screening for prostate cancer. Eur. J. Cancer 2011; 47: 2698-2705.
Pogodin-Hannolainen, D., Juusela, H., Tammela, T. L. J., Ruutu, M., Aro, J., Määttänen, L. and Auvinen, A.: Prostate cancer screening: a survey of attitudes and practices among Finnish physicians in 1999 and 2007. J. Med. Screen. 2011; 18: 46-49.
van Vugt, H.A., Roobol, M.J., Kranse, R., Määttänen, L., Finne, P., Hugosson, J., Bangma, C.H., Schröder, F.H. and Steyerberg, E.W.: Prediction of prostate cancer in unscreened men: External validation of a risk calculator. Eur. J. Cancer 2011; 47: 903-909.
Kilpeläinen, T.P., Auvinen, A., Määttänen, L., Kujala, P., Stenman, U.-H. and Tammela, T.L.J.: Results of the three rounds of the Finnish prostate cancer screening trial - the incidence of advanced cancer is decreased by screening. Int. J. Cancer 2010; 127: 1699-1705.
Kilpeläinen, T.P., Tammela, T.L.J., Määttänen, L., Kujala, P., Stenman, U.-H., Ala-Opas, M., Murtola, T.J. and Auvinen, A.: False-positive screening results in the Finnish prostate cancer screening trial. Brit. J. Cancer 2010; 102: 469-474.
Laurila, E., van der Kwast, T., Bubendorf, L., di Lollo, S., Pihl, C.-G., Ciatto, S., Hugosson, J., Määttänen, L., Roobol, M.J. and Kujala, P.M.: Detection rates of cancer, high grade PIN and atypical lesions suspicious for ca ncer in the European Randomized Study of Screening for Prostate Cancer. Eur. J. Cancer 2010; 46: 3068-3072.
Malmi, H., Ruutu, M., Määttänen, L., Stenman, U.-H., Juusela, H., Tammela, T.L.J. and Auvinen, A.: Why do men opt out of prostate-cancer screening? Attitudes and perception among participants and non-participants of a screening trial. BJU Int. 2010; 106: 472-477.
Murtola, T.J., Tammela, T.L.J., Määttänen, L., Huhtala, H., Platz, E.A., Ala-Opas, M., Stenman, U.-H. and Auvinen, A.: Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int. J. Cancer; 127: 1650-1659.
Otto, S.J., Moss, S.M., Määttänen, L., Roobol, M., Zappa, M., Nelen, V., Kwiatkowski, M., Villers, A., Hugosson, J., Berenguer Sanchez, A. and de Koning, H.J.: PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. Eur. J. Cancer 2010; 46: 3053-3060.
Laurila, M., Tammela, T.L.J., Auvinen, A., Isola, J., Visakorpi, T., Luukkaala, T., Määttänen, L., Ruutu, M., Ala-Opas, M., Mildh, M. and Martikainen, P.: Biological aggressiveness of prostate cancer in the Finnish screening trial Int. J. Cancer 2009; 124: 547-552.
Murtola, T.J., Tammela, T.L.J., Määttänen, L., Ala-Opas, M., Stenman, U.H. and Auvinen, A.: Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. British J. Cancer 2009; 101: 843-848.
Schröder, F.H., Hugosson, J., Roobol, M.J., Tammela, T.L.J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L.J., Recker, F., Berenguer, A., Määttänen, L., Bangma, C.H., Aus, G., Villers, A., Rebillard, X., van der Kvast, T., Blijenberg, B.G., Moss, S.M. and de Koning, H.J. and Auvinen, A. for the ERSPC Investigators: Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009; 360: 1320-1328.
Finne, P., Auvinen, A., Määttänen, L., Tammela, T.L., Ruutu, M., Juusela, H., Martikainen, P., Hakama, M. and Stenman, U.-H.: Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0mug per liter. Eur. Urol. 2008; 54: 362-370.
Mäkinen, T., Karhunen, P., Aro, J., Lahtela, J., Määttänen, L. and Auvinen, A.: Assessment of causes of death in a prostate cancer screening trial. Int. J. Cancer 2008; 122: 413-417.
Murtola, T.J., Tammela, T.L.J., Määttänen, L., Hakama, M. and Auvinen, A.: Prostate cancer risk among users of finasteride and alpha-blockers - A population based case-control study. Eur. J. Cancer 2007; 43: 775-781.
Määttänen, L.: Performance of the Finnish prostate cancer screening trial based on process indicators. Doctor's Thesis. University of Tampere. Acta Universitatis Tamperensis No. 1247. Tampere 2007.
Määttänen, L., Hakama, M., Tammela, T.L.J., Ruutu, M., Ala-Opas, M., Juusela, H., Martikainen, P., Stenman, U.-H. and Auvinen, A.: Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. Br. J. Cancer 2007; 96: 56-60.
Roobol, M.J., Zappa, M., Määttänen, L. and Ciatto, S.: The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Prostate 2007; 67: 439-446.
van der Kwast, T.H., Ciatto, S., Martikainen, P.M., Hoedemaeker, R., Laurila, m., Pihl, C.-G., Hugosson, J., Neetens, I., Nelen, V., Di Lollo, S., Roobol, M.J., Määttänen, L., Santonja, C., Moss, S. and Schröder, F.H.: Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer Int. J. Cancer 2006; 118: 2538-2542.
Auvinen, A., Määttänen, L., Finne, P., Stenman, U.H., Aro, J., Juusela, H., Rannikko, S., Tammela, T.L. and Hakama, M.: Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial. Int. J. Cancer 2004; 111: 940-943.
Mäkinen, T., Tammela, T.L.J., Stenman, U.-H., Määttänen, L., Aro, J., Juusela, H., Martikainen, P., Hakama, M. and Auvinen, A.: Second round results of the Finnish population-based prostate cancer screening trial. Clin. Cancer Res. 2004; 10: 2231-2236.
Finne, P., Stenman, U.-H., Määttänen, L., Mäkinen, T., Tammela, T.L.J., Martikainen, P., Ruutu, M., Ala-Opas, M., Aro, J., Karhunen, P.J., Lahtela, J., Rissanen, P., Juusela, H., Hakama, M. and Auvinen, A.: The The Finnish trial of prostate cancer screening: where are we now? BJU Int. 2003; 92: Suppl. 2: 22-26.
Mäkinen, T., Tammela, T.L., Hakama, M., Stenman, U.-H., Rannikko, S., Aro, J., Juusela, H., Määttänen, L. and Auvinen, A.: Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen. Clin. Cancer Res. 2003; 9: 2435-2439.
van der Kwast, T.H., Roobol, M.J., Wildhagen, M.F., Martikainen, P.M., Määttänen, L., Pihl, C.-G., Santonja, C., Bubendorf, L., Neetens, I., di Lillo, S. and Hoedemaeker, R.F.: Consistency of prostate cancer grading results in screened populations across Europe. BJU Int. 2003; 92: Suppl. 2: 88-91.
Auvinen, A., Määttänen, L., Stenman, U.-H., Tammela, T., Rannikko, S., Aro, J., Juusela, H. and Hakama, M.: Lead-time in prostate cancer screening (Finland). Cancer Causes Control 2002; 13: 279-285.
Finne, P., Auvinen, A., Aro, J., Juusela, H., Määttänen, L., Rannikko, S., Hakama, M., Tammela, T. and Stenman, U.-H.: Who should be biopsied in prostate cancer screening? Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur. Urol. 2002; 41: 619-627.
Mäkinen, T., Tammela, T.L.J., Stenman, U.-H., Määttänen, L., Rannikko, S., Aro, J., Juusela, H., Hakama, M. and Auvinen, A.: Family history and prostate cancer screening with prostate-specific antigen. J. Clin. Oncol. 2002; 20: 2658-2663.
Isola, J., Auvinen, A., Poutiainen, M., Kakkola, L., Järvinen, T.H.A., Määttänen, L., Stenman, U.-H., Tammela, T., Hakama, M. and Viskorpi, T.: Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer. J. Urol. 2001; 165: 1569-1574.
Miller, A.B., Madalinska, J.B., Church, T., Crawford, D., Essink-Bot, M.L., Goel, V., de Koning, H.J., Määttänen, L. and Pentikäinen, T.: Health-related quality of life and cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US prostate, lung colon and ovary trial. Eur. J. Cancer 2001; 37: 2154-2160.
Mäkinen, T., Tammela, T.L.J., Hakama, M., Stenman, U.-H., Rannikko, S., Aro, J., Juusela, H., Määttänen, L. and Auvinen, A.: Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests. J. Urol. 2001; 166: 1339-1342.
Määttänen, L., Auvinen, A., Stenman, U.-H., Tammela, T., Rannikko, S., Aro, J., Juusela, H. and Hakama, M.: Three-year results of the Finnish prostate cancer screening trial. J. Natl. Cancer Inst. 2001; 93: 552-553.
Finne, P., Auvinen, A., Koistinen, H., Zhang, W-M., Määttänen, L., Rannikko, S., Tammela, t., Seppälä, M., Hakama, M. and Stenman, U.-H.: Insulin-like growth factor I not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J. Clin. Endocrinol. Metab. 2000; 85: 2744-2747.
Finne, P., Finne, R., Auvinen, A., Juusela, H., Aro, J., Määttänen, L., Hakama, M., Rannikko, S., Tammela, T.L.J. and Stenman, U.-H.: Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 2000; 56: 418-422.
Finne, P., Zhang, W.M. , Auvinen, A., Leinonen, J., Määttänen, L., Tammela, T.L.J. and Stenman, U.-H.: Use of the complex between prostate-specific antigen and alpha 1-protease inhibitor in screening for prostate cancer. J. Urol. 2000; 164: 1956-1960.
Määttänen, L., Auvinen, A., Stenman, U.-H., Rannikko, S., Tammela, T., Aro, J., Juusela, H. and Hakama, M.: European randomized study of prostate cancer screening: first-year results of the Finnish trial. Br. J. Cancer 1999; 79: 1210-1214.